-- BQE Water (BQE.V) 週四公佈，受營收成長的推動，第四季獲利成長 36%。 截至 12 月 31 日的三個月內，淨利潤從去年同期的 121 萬美元增至 165 萬美元。 該季度營收從去年同期的 509 萬美元增至 750 萬美元。 在 2026 年展望中，該公司表示，「幾項大型技術服務合約的前景清晰明朗，確定性高，預計 2026 年上半年業績強勁。」該公司補充道，Eagle 礦應急處理系統的運營服務將持續到 2026 年 6 月。 「由於我們沒有超過 6 個月的營運協議，我們將繼續把該項目計入技術服務項下，」該公司補充道。 BQE 指出，其新建的水生毒理學實驗室將在第二季末之前投入運營，並能夠進行一系列專業調查測試。執行長大衛·克拉托奇維爾表示：「憑藉全年強勁的成長勢頭，我們在第四季度幾乎在所有關鍵指標上都創下了年度業績的新紀錄。第四季度，我們完成了鷹礦的運營季，排放了超過100萬立方米的清潔水用於緊急處理，並已調動團隊做好準備，執行布里塔尼亞礦處理廠為期20年的運營服務。 “2026年對於BQE來說將是另一個增長之年，我們預計將繼續在鷹礦進行緊急處理，重啟/恢復我們在2025年運營的7個礦場的運營，並接管位於卑詩省、魁北克省和育空地區的另外4個處理廠的運營。” 該公司股票在多倫多證券交易所創業板收盤上漲0.50美元，報73美元。
Related Articles
Asia
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
$KOSDAQ:440110
Asia
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.
$BOM:524715$NSE:SUNPHARMA